Patents Assigned to Lupin Limited
-
Patent number: 10696636Abstract: The present invention provides compound of formula (XVII), wherein P is hydroxyl protecting group; R2 and R3 are independently lower alkyl or R2 and R3 can be alkyl and joined to form a 5-, 6- or 7-membered ring; R4 is lower alkyl, and process for its preparation.Type: GrantFiled: December 15, 2016Date of Patent: June 30, 2020Assignee: Lupin LimitedInventors: Girij Pal Singh, Dhananjai Shrivastava, Harishchandra Sambhaji Jadhav, Pramod Sudhakar Utekar, Digambar Yashwant Salunke
-
Publication number: 20200101068Abstract: Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein ring Ar, ring B, R1-R5, X, Y, p, q, r, and s are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.Type: ApplicationFiled: August 13, 2016Publication date: April 2, 2020Applicant: Lupin LimitedInventors: Navnath Popat Karche, Ajay Ramchandra Tilekar, Sanjay Pralhad Kurhade, Ganesh Rajaram Jadhav, Nishant Ramniwasji Gupta, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 10556942Abstract: The present invention relates to the purification of TNFR:Fc fusion protein. More specifically related to process of purification of TNFR:Fc fusion protein wherein the HCP is reduced. The present invention is directed to the use of mixed-mode chromatography and/or affinity chromatography to produce TNFR:Fc fusion protein which is substantially free of at least one of the protein degrading enzyme present in HCP.Type: GrantFiled: June 13, 2015Date of Patent: February 11, 2020Assignee: LUPIN LIMITEDInventors: Abir Banerjee, Chandranath Ganapathy, Sorab Rustom Mody, Ashok Mishra
-
Patent number: 10556069Abstract: An inhaler device comprising: a housing (2), a base plate (4) covering the housing (2), a medicament holder (10) integrated with the base plate (4), a mouthpiece (3) sitting over the base plate (4), a lid (1) which covers the mouthpiece (3), at least one piercing element (11), an actuating member (5), a spring (12), and is characterized in that the inhaler device is a two hinges system (6,8) wherein the base plate (4) is joined to hinge (6); the mouthpiece (3) and the lid (1) are joined to the hinge (8).Type: GrantFiled: February 23, 2015Date of Patent: February 11, 2020Assignee: LUPIN LIMITEDInventors: Vishwajit Bhide, Raghuram Amperayani Pattabhi, Rohini Pimple, Bishu Choubey
-
Publication number: 20200024321Abstract: The invention provides a method for the large-scale preparation of small peptides using recombinant DNA technology. Overexpression of small peptides, such as liraglutide precursor, as concatemers, improves the overall efficiency of the process due to increased yields per batch of the biologically active peptide. Digestion of these concatemers by combinations of specific enzymes yields the desired peptide monomer in large quantities.Type: ApplicationFiled: March 20, 2018Publication date: January 23, 2020Applicant: Lupin LimitedInventors: Sudharti GUPTA, Shardul Sumantrao SALUNKHE, Brajesh VARSHNEY, Rustom Sorab MODY
-
Patent number: 10479776Abstract: The present invention provides an improved process for the preparation of Efinaconazole in higher yield by the ring-opening addition reaction of epoxytriazole with 4-methylenepiperidine or its acid addition salt under mild conditions without using a large excess of 4-methylenepiperidine in the presence of an alkali or an alkaline earth metal halide.Type: GrantFiled: May 10, 2016Date of Patent: November 19, 2019Assignee: LUPIN LIMITEDInventors: Sachin Arun Sasane, Devendrakumar Paramsukh Varma, Rajesh Harishankar Vyas, Nandu Baban Bhise, Girij Pal Singh, Krishnat Hanmant Kumbhar
-
Patent number: 10479787Abstract: The present invention provides process for preparation of dihydroxy benzoquinoline compound (III) comprising reacting dihydroxy isoquinoline compound (IV) or a salt thereof with (2-acetyl-4-methyl-pentyl)-trimethyl-ammonium iodide (V) and further converting it to tetrabenazine (I) and deutetrabenazine (II).Type: GrantFiled: April 12, 2017Date of Patent: November 19, 2019Assignee: Lupin LimitedInventors: Tushar Nandkumar Despande, Dnyaneshwar Tukaram Singare, Yogesh Dadaji Pawar, Yuvraj Atmaram Chavan, Purna Chandra Ray, Girij Pal Singh
-
Patent number: 10377712Abstract: The present invention provides an improved process for preparation of an intermediate of apremilast. The present invention also provides an improved process for preparation of apremilast. This invention also provides novel polymorphs of apremilast. The present invention also provides pharmaceutical compositions of novel polymorphs of apremilast. This invention also provides a process for preparation of novel polymorphs of apremilast, which are cost-effective, robust, and viable at plant scale.Type: GrantFiled: May 26, 2016Date of Patent: August 13, 2019Assignee: LUPIN LIMITEDInventors: Palash Sanphui, Ananda Pundlik Sapdhare, Arunkumar Digambar Patil, Hemraj Mahadeorao Lande, Gurvinder Pal Singh, Puma Chandra Ray, Nandu Baban Bhise, Girij Pal Singh, Mithun Dasharath Surwase, Shantanu Gokuldas Varade, Govind Dnyanoba Ausekar, Radhakrishna Bhikaji Shivdavkar
-
Publication number: 20190192490Abstract: A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.Type: ApplicationFiled: November 26, 2018Publication date: June 27, 2019Applicant: Lupin Limited ( Research Park)Inventors: Harshal Anil Jahagirdar, Kishore Kumar Konda, Satish Kumar Dalal, Shirishkumar Kulkarni
-
Patent number: 10329571Abstract: The present invention relates to the dual, independent cistron expression system in a single vector for the production of protein of interest proteins and peptides expressed as insoluble inclusion bodies formed in the bacteria E. coli. The present invention also provides the process for the expression of protein of interest using said bicistronic vector.Type: GrantFiled: July 9, 2015Date of Patent: June 25, 2019Assignee: Lupin LimitedInventors: Shardul Salunkhe, Brajesh Varshney, Sudheerbabu Soorapaneni
-
Patent number: 10292981Abstract: The present invention relates to compounds of Formula (I), along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).Type: GrantFiled: July 6, 2017Date of Patent: May 21, 2019Assignee: LUPIN LIMITEDInventors: Nageswara Rao Irlapati, Gokul Keruji Deshmukh, Vijay Pandurang Karche, Santosh Madhukar Jachak, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20190135803Abstract: The present invention provides process for preparation of dihydroxy benzoquinoline compound (III) comprising reacting dihydroxy isoquinoline compound (IV) or a salt thereof with (2-acetyl-4-methyl-pentyl)-trimethyl-ammonium iodide (V) and further converting it to tetrabenazine (I) and deutetrabenazine (II).Type: ApplicationFiled: April 12, 2017Publication date: May 9, 2019Applicant: Lupin LimitedInventors: Tushar Nandkumar DESPANDE, Dnyaneshwar Tukaram SINGARE, Yogesh Dadaji PAWAR, Yuvraj Atmaram CHAVAN, Purna Chandra RAY, Girij Pal SINGH
-
Patent number: 10278963Abstract: A timed release pharmaceutical composition comprising donepezil is provided, wherein the composition exhibits the in vitro dissolution profile when tested in a Paddle dissolution apparatus at 50 rpm in 900 ml 6.8 buffer at 37° C., less than about 20% w/w of donepezil is released in 3 to 6 hrs, and more than 90% w/w of donepezil is released after 12 hrs.Type: GrantFiled: February 27, 2014Date of Patent: May 7, 2019Assignee: LUPIN LIMITEDInventors: Dhananjay Sadashiv Bakhle, Chirag Anilkumar Shah, Snehal Ameet Gadve, Neha Sharma, Sajeev Chandran, Ashish Ashokrao Deshmukh
-
Publication number: 20190110994Abstract: Present invention discloses the stable pharmaceutical composition comprising premix of dapagliflozin with at least one pharmaceutically acceptable excipient(s) and process for preparation thereof. Dapagliflozin is highly hygroscopic and hence it is difficult to formulate dapagliflozin as stable pharmaceutical composition. Present invention discloses the stable pharmaceutical composition of dapagliflozin comprising premix of dapagliflozin with lactose.Type: ApplicationFiled: March 30, 2017Publication date: April 18, 2019Applicant: LUPIN LIMITEDInventors: Chandrakant SHERVI, Byomakesh PANDA, Murali Krishna BHAVARISETTI, Subhasis DAS, Vijaya Kumar THOMMANDRU
-
Patent number: 10259790Abstract: The present invention is directed to polymorphic forms of Pitavastatin sodium and processes for preparation of the same.Type: GrantFiled: April 6, 2018Date of Patent: April 16, 2019Assignee: LUPIN LIMITEDInventors: Narendra Dattatray Mane, Sagar Purushottam Nehate, Himanshu Madhav Godbole, Girij Pal Singh
-
Patent number: 10251850Abstract: The present invention provides process for preparation of cysteamine bitartrate comprising reacting cysteamine or its salt with tartaric acid. The present invention further provides crystalline form L1 of cysteamine bitartrate having characteristic diffraction peaks at 10.36, 14.54, 17.23, 18.03, 19.24, 20.76, 21.20, 22.02, 23.37, 23.64, 27.71, 28.28, 29.26, 31.33, 32.84, 33.83, 35.51, 36.74±0.2 degree two theta in an X-ray diffraction pattern and process for preparation thereof. The present invention provides crystalline form L2 of cysteamine bitartrate having characteristic diffraction peaks at 7.4, 10.3, 11.0, 11.4, 14.4, 14.9, 18.6, 19.4, 20.1, 20.8, 21.9, 22.3, 22.5, 23.5±0.2 degree two theta in an X-ray diffraction pattern and process for preparation thereof.Type: GrantFiled: January 11, 2018Date of Patent: April 9, 2019Assignee: LUPIN LIMITEDInventors: Pankaj Ramchandra Chaudhari, Sukhdeo Sampat Gunjal, Raju Muktaji Walunj, Anurag Trivedi, Rajinder Singh Siyan, Nandu Baban Bhise, Girij Pal Singh
-
Patent number: 10239869Abstract: The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention.Type: GrantFiled: September 3, 2016Date of Patent: March 26, 2019Assignee: LUPIN LIMITEDInventors: Vidya Ramdas, Rajeshkumar Maganlal Loriya, Moloy Banerjee, Pradeep Rangrao Patil, Advait Arun Joshi, Laxmikant Shamlal Datrange, Deepak Sahebrao Walke, Talha Hussain Khan, Amit Kumar Das, Ganesh Navinchandra Gote, Vaibhav Madhukar Kalhapure, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20190076536Abstract: A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract.Type: ApplicationFiled: April 2, 2018Publication date: March 14, 2019Applicant: LUPIN LIMITEDInventors: Harshal Anil JAHAGIRDAR, Rajesh KULKARNI, Shirishkumar KULKARNI
-
Patent number: 10227317Abstract: Disclosed herein a process for the isolation of intermediate of Vortioxetine in a solid state form and an improved, commercially viable and industrially advantageous process for the preparation of vortioxetine or a pharmaceutically acceptable salt thereof, in high yield and purity.Type: GrantFiled: February 24, 2016Date of Patent: March 12, 2019Assignee: LUPIN LIMITEDInventors: Girij Pal Singh, Dhananjai Srivastava, Paramvir Bhadwal, Inamus Saqlain Ansari, Nilesh Shashikant Bhawsar
-
Publication number: 20190029968Abstract: The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.Type: ApplicationFiled: September 28, 2018Publication date: January 31, 2019Applicant: LUPIN LIMITEDInventors: Shirishkumar Kulkarni, Satish Kumar Dalal, Harshal Jahagirdar, Kishore Kumar Konda